Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan IMMU-132, a Promising Late-Stage ADC for Solid Tumors

Source :: Women's Health Weekly. March 2, 2017, 86
Publication Year :: 2017
Abstract: 2017 MAR 2 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, announced a development and license [...]

Subjects :: Immunomedics Inc. -- Licensing agreements
Seagen Inc. -- Licensing agreements
Biological products industry -- Licensing agreements
Women -- Health aspects
Medical research
Medicine, Experimental
Tumors
Biological products -- Licensing agreements
Biotechnology industry -- Licensing agreements
Company licensing agreement
Health
Women's issues/gender studies

Tools